van Oort IM - Search Results

1

Homologous recombination repair deficient prostate cancer represents an immunologically distinct subtype.

van Wilpe S, Simnica D, Slootbeek P, van Ee T, Pamidimarri Naga S, Gorris MAJ, van der Woude LL, Sultan S, Koornstra RHT, van Oort IM, Gerritsen WR, Kroeze LI, Simons M, van Leenders GJLH, Binder M, de Vries IJM, Mehra N. van Wilpe S, et al. Among authors: van oort im, van der woude ll, van ee t, van leenders gjlh. Oncoimmunology. 2022 Jul 1;11(1):2094133. doi: 10.1080/2162402X.2022.2094133. eCollection 2022. Oncoimmunology. 2022. PMID: 35800157 Free PMC article.

2

Body mass index as a prognostic marker for biochemical recurrence in Dutch men treated with radical prostatectomy.

van Roermund JG, Kok DE, Wildhagen MF, Kiemeney LA, Struik F, Sloot S, van Oort IM, Hulsbergen-van de Kaa CA, van Leenders GJ, Bangma CH, Witjes JA. van Roermund JG, et al. Among authors: van oort im, van leenders gj. BJU Int. 2009 Aug;104(3):321-5. doi: 10.1111/j.1464-410X.2009.08404.x. Epub 2009 Feb 11. BJU Int. 2009. PMID: 19220264

3

Cabazitaxel in patients with metastatic castration-resistant prostate cancer: results of a compassionate use program in the Netherlands.

Wissing MD, van Oort IM, Gerritsen WR, van den Eertwegh AJ, Coenen JL, Bergman AM, Gelderblom H. Wissing MD, et al. Among authors: van oort im, van den eertwegh aj. Clin Genitourin Cancer. 2013 Sep;11(3):238-250.e1. doi: 10.1016/j.clgc.2013.04.004. Epub 2013 May 6. Clin Genitourin Cancer. 2013. PMID: 23659772

4

Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and Enzalutamide.

Benoist GE, Hendriks RJ, Mulders PF, Gerritsen WR, Somford DM, Schalken JA, van Oort IM, Burger DM, van Erp NP. Benoist GE, et al. Among authors: van oort im, van erp np. Clin Pharmacokinet. 2016 Nov;55(11):1369-1380. doi: 10.1007/s40262-016-0403-6. Clin Pharmacokinet. 2016. PMID: 27106175 Free PMC article. Review.

5

Drug-drug interaction potential in men treated with enzalutamide: Mind the gap.

Benoist GE, van Oort IM, Smeenk S, Javad A, Somford DM, Burger DM, Mehra N, van Erp NP. Benoist GE, et al. Among authors: van oort im, van erp np. Br J Clin Pharmacol. 2018 Jan;84(1):122-129. doi: 10.1111/bcp.13425. Epub 2017 Oct 18. Br J Clin Pharmacol. 2018. PMID: 28881501 Free PMC article.

6

223Ra Therapy in Patients With Advanced Castration-Resistant Prostate Cancer With Bone Metastases: Lessons from Daily Practice.

van der Doelen MJ, Kuppen MCP, Jonker MA, Mehra N, Janssen MJR, van Oort IM, Gerritsen WR. van der Doelen MJ, et al. Among authors: van oort im. Clin Nucl Med. 2018 Jan;43(1):9-16. doi: 10.1097/RLU.0000000000001904. Clin Nucl Med. 2018. PMID: 29166331

7

Difficulties in Pain Management Using Oxycodone and Fentanyl in Enzalutamide-Treated Patients With Advanced Prostate Cancer.

Westdorp H, Kuip EJM, van Oort IM, Kramers C, Gerritsen WR, Vissers KCP. Westdorp H, et al. Among authors: van oort im. J Pain Symptom Manage. 2018 Apr;55(4):e6-e8. doi: 10.1016/j.jpainsymman.2017.11.016. Epub 2017 Nov 22. J Pain Symptom Manage. 2018. PMID: 29175468 Free article. No abstract available.

8

The Combination of Enzalutamide and Opioids: A Painful Pitfall?

Benoist GE, van Oort IM, Burger DM, Koch BCP, Mehra N, van Erp NP. Benoist GE, et al. Among authors: van oort im, van erp np. Eur Urol. 2019 Feb;75(2):351-352. doi: 10.1016/j.eururo.2018.09.011. Epub 2018 Sep 21. Eur Urol. 2019. PMID: 30245086 No abstract available.

9

Immediate treatment vs. active-surveillance in very-low-risk prostate cancer: the role of patient-, tumour-, and hospital-related factors.

Jansen H, van Oort IM, van Andel G, Wijsman BP, Pos FJ, Hulshof MCCM, Hulsbergen-van de Kaa CA, van Leenders GJLH, Fütterer JJ, Somford DM, Busstra MB, van Moorselaar RJA, Kiemeney LA, Aben KKH. Jansen H, et al. Among authors: van oort im, van andel g, van moorselaar rja, van leenders gjlh. Prostate Cancer Prostatic Dis. 2019 May;22(2):337-343. doi: 10.1038/s41391-018-0109-y. Epub 2018 Nov 14. Prostate Cancer Prostatic Dis. 2019. PMID: 30429595

10

Patient Selection for Radium-223 Therapy in Patients With Bone Metastatic Castration-Resistant Prostate Cancer: New Recommendations and Future Perspectives.

van der Doelen MJ, Mehra N, Hermsen R, Janssen MJR, Gerritsen WR, van Oort IM. van der Doelen MJ, et al. Among authors: van oort im. Clin Genitourin Cancer. 2019 Apr;17(2):79-87. doi: 10.1016/j.clgc.2018.11.008. Epub 2018 Nov 22. Clin Genitourin Cancer. 2019. PMID: 30558834 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

172 results

Search Page

Filters